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Mycobacterium marinum (M. marinum) is a ubiquitous waterborne organism that grows optimally at temperatures around 30∘C.
It is a nontuberculousMycobacterium found in nonchlorinated water with worldwide prevalence. It is the most common atypical
Mycobacterium that causes opportunistic infection in humans.M. marinum can cause superficial infections and localized invasive
infections in humans, with the hands being the sites most frequently affected. It can cause skin lesions, which are either single,
papulonodular lesions, confined to an extremity, or may resemble cutaneous sporotrichosis. This infection can also cause deeper
infections including tenosynovitis, bursitis, arthritis, and osteomyelitis. Disseminated infections and visceral involvements have
been reported in immunocompromised patients. We here report a case of severe deep soft tissue infection with necrotizing fasciitis
and osteomyelitis of the left upper extremity (LUE) caused byM. marinum in an immunocompromised patient.
1. Introduction
Mycobacterium marinum was first isolated in 1926 by Aron-
son from salt water fish carcasses in the Philadelphia aquar-
ium [1]. Baker andHagan discovered that themycobacterium
caused tuberculosis in fresh water platyfish and called it
M. platypoecilus [2]. In 1951, it was recognized as a human
pathogen by Linell and Norden who isolated it from the skin
lesions of swimmers from the swimming pool in Sweden [3].
M.marinum is a nontuberculousmycobacterium belong-
ing to Runyon group I, a photochromogen [4]. M. marinum
has a worldwide distribution and primarily infects fish
that can secondarily contaminate aquaria, swimming pools,
rivers, and seawater. When transmitted to animals such as
amphibians, fish, mice, and bats, it can be highly prevalent
in fish tanks and cause infections and death in various fish
species [4]. The colonies form a yellow pigment when the
culture medium on which they are growing is exposed to
light. Optimal growth is at 30 to 32∘C. It grows slowly
or not at all at 37∘C. This organism will grow nicely on
standard mycobacterial media and produces smooth and
shiny colonies in an average of 10 to 28 days, though the
cultures should be held for 6 weeks if negative. M. marinum
preferentially grows at cold temp between 30 to 32∘C and
thus, infections with M. marinum are usually localized
primarily to the skin. Less commonly it extends to involve
deeper structures such as joints and tendons. Dissemination
has been reported, but is distinctly unusual [5]. In general,
M. marinum infection in humans is comparatively rare. The
approximate annual incidence in the United States is 0.27
confirmed cases per 100,000 inhabitants [6]. In 90% of cases,
infection takes place via trauma to the upper extremity and is
not transmittable from person to person [7].
We searched the published English literature for cases of
severe deep soft tissue infection and osteomyelitis caused by
M. marinum both in immunocompromised and immuno-
competent individuals. We found eleven published cases of
adult M. marinum complicated with osteomyelitis. Four of
them had compromised immune systems. This case review
aims to focus on severe deep soft tissue infection and
osteomyelitis caused byM. marinum.
2. Case Report
Patient is a 64-year-old Caucasian male presented to the
emergency room at the end of December at our facility
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Figure 1: Inflammatory nodules on the left hand on second
admission.
Figure 2:MRI of the left arm showedmultiple ulcerations extending
from skin into subcutaneous fat with appearance concern for
necrotizing fasciitis and osteomyelitis.
with worsening left arm swelling. Two weeks ago, he was
initially admitted for the right arm swelling and tenderness.
He, at baseline, has been on leflunomide for three years
for treatment of rheumatoid arthritis and previously was on
prednisone for the same reason. Patient reported that, inmid-
November, he started to experience significant pain in both
wrists and was evaluated at the rheumatologist office for pos-
sible rheumatoid arthritis flare. He had received steroid injec-
tions in bilateral wrists. During his first admission two weeks
prior, he was diagnosed with deep abscesses of right upper
extremity (RUE)which has later gotten incision anddrainage.
At that time, only bacterial cultures were sent, which
grew methicillin-sensitive Staphylococcus aureus. Patient was
discharged home on trimethoprim/sulfamethoxazole oral
tablets but readmitted seven days later with pain and pustules
nowmainly on all of the fingers of the left forearm (Figure 1).
He again underwent drainage and bacterial and acid fast
bacilli smear and cultures were sent. M. marinum was iden-
tified phenotypically in our lab when the culture grew at 30
degrees Celsius.The sample was also sent out for biochemical
sequence and further identified as M. marinum (Nichols
Institute, Chantilly, VA). He was empirically treated with
intravenous imipenem, linezolid, and azithromycin. During
this second admission, magnetic resonance imaging (MRI)
of the left arm was done which showed multiple ulcerations
extending from the skin surface into the subcutaneous fat
with the largest visualized at the palmar aspect of the wrist,
Table 1: Susceptibility testing result ofM. marinum in our patient.
Organism
M. marinum with
minimal inhibitory
concentration (MIC)
values
Amikacin 8 susceptible (S)
Ciprofloxacin 8 resistance (R)
Clarithromycin 2 S
Doxycycline 16 R
Ethambutol 4 S
Ethionamide 2.5
Isoniazid >8
Linezolid 4
Moxifloxacin 4 R
Rifampin 2 R
Rifabutin ≤0.25 S
Streptomycin 32
Trimethoprim/sulfamethoxazole 2/38 S
extending deep to the level of the carpal tunnel/hook of
the hamate, at the dorsal and ulnar aspects of the mid-
and distal forearm at two sites and at the ulnar aspect of
the distal forearm suggesting tenosynovitis with necrotizing
fasciitis. He recovered well from the surgery and was dis-
charged on doxycycline and azithromycin while waiting for
susceptibility. Despite being adherent to this regimen for four
weeks, he was ultimately readmitted a third time with new
abscess formation on medial aspect of his proximal LUE and
repeated MRI showing osteomyelitis of the left distal ulna
(Figure 2). Susceptibility test with minimal inhibitor concen-
tration (MIC) (Focus Diagnostics, Inc., Cypress, CA) came
back withM. marinum resistant to doxycycline and rifampin
(Table 1). He underwent the third incision and drainage with
the skin graft for his LUE. Therapy was then changed to
azithromycin and trimethoprim/sulfamethoxazole based on
the susceptibility result (Table 1). Because of extensive disease
and slow improvement on therapy, our patient received nine
months of antibiotics therapy with good response (Figure 3).
He is still being followed by infectious diseases and plastic
surgery.
3. Methods
We searched the English language literature published until
August 2014 in the PubMed database. Relevant studies were
identified using various key word combinations including
“mycobacterium,” “marinum,” “osteomyelitis,” and “treat-
ment.” No lower publication date limit was set. Eleven
published cases of Mycobacterium marinum osteomyelitis
were ascertained. The clinical characteristics including age,
gender, predisposing factors, duration of therapy, clinical
outcome, and list of antimicrobials used were summarized in
Table 2.
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Figure 3: Patient’s left hand at his 9-month follow-up.
Table 2: Cases ofM. marinum osteomyelitis in the literature review with treatment and clinical outcome.
Author Year 𝑛 Age Sex Immunestatus OM site Source
Chemotherapy +
surgical
debridement
Duration Outcome
Jolly and
Seabury [8] 1972 1 36 M Normal Finger Fishing None N/a Amputation
Wendt et al. [9] 1986 1 47 F Normal Finger Unknown INH, rifampin,and ethambutol 3 weeks Amputation
Clark et al. [10] 1990 1 56 M Normal Finger Fishing/steroidinjection
Minocycline,
rifampin, and
ethambutol
9 months Recovered
Vazquez and
Sobel [11] 1992 1 62 F Normal Finger Fish tank
INH, rifampin,
and bactrim 3 weeks Amputation
Harth et al. [12] 1994 1 56 M Normal Finger Fish tank/steroidinjection
Ciprofloxacin,
ethambutol, and
rifampin
12 months Recovered
Alloway et al.
[13] 1995 1 71 M Normal Finger Fishing
Ciprofloxacin,
ethambutol, and
rifampin
12 months Recovered
Barton et al. [14] 1997 1 48 F Deficient Finger Fish tank Doxycycline 6 months Recovered
Shih et al. [15] 1997 1 52 F Normal Finger Fish dealer Clarithromycinand ethambutol 18 months Recovered
Wilson et al. [16] 2003 1 47 M Deficient Foot(talus) None
Rifabutin and
ciprofloxacin 3 months Amputation
Sivan et al. [17] 2008 1 66 M Deficient Leg Fish tank
Rifampicin,
ethambutol, and
moxifloxacin
12 months Recovered
Present case 2014 1 64 M Deficient Arm Fishing Azithromycinand bactrim 9 months Recovered
Barton et al., 1997 [14]: immunosuppressive therapy for rheumatoid arthritis and fibrosing alveolitis.
Wilson et al., 2003 [16]: acquired immunodeficiency syndrome.
Sivan et al., 2008 [17]: immunosuppressive therapy for bullous pemphigoid.
Present-2014: immunosuppressive therapy for rheumatoid arthritis.
4. Discussion
Mycobacterium marinum is a nontuberculous mycobac-
terium belonging to Runyon group I, a photochromogen.
From the literature review, its infection occurs approximately
about 2–6 weeks after direct inoculation of the organism
either from fish fins and bites or from the handling of
aquariums. Incubation period is normally about 2–6 weeks.
However, there are some cases reporting an incubation time
of 2 to 4 months and longer, with some cases reporting an
incubation period as long as 9 months due to the slow-
growing nature of this organism [6].
There aremany different clinical presentations ofM.mar-
inum infection. In immunocompetent patient, most com-
monly it appears as a solitary papulonodular lesion on an
extremity. In particular, these lesions tend to occur over a
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prominence that has a predisposition to be abraded, such
as finger, hand, or knee. A history of preceding minor
trauma is common and an occupation or hobby that resulted
in a likely environmental water exposure is the rule [18].
Inflammatory nodules or abscesses can develop in severely
immunosuppressed patient, usually in a sporotrichotic type
of distribution [3]. This “sporotrichoid” disease begins with
distal inoculation and may lead to the development of
nodular lymphangitis. Over a period of months, localized
cutaneous disease can spread to deeper soft tissues, causing
tenosynovitis, arthritis, bursitis, and/or osteomyelitis of the
underlying bone; it can also be life-threatening, and lesions
may or may not be painful [6]. Infections with M. marinum
can be theoretically classified into four different clinical cat-
egories to help in guiding treatment options. Type I includes
single or limited (1–3 lesions) superficial cutaneous infections
(ulcerated, crusted, or verrucous plaques or nodules). Type
II includes numerous (>3) lesions in a sporotrichoid distri-
bution pattern or with inflammatory nodules, abscesses, and
granulomas. Type III includes deep infectionswith orwithout
skin involvement, including tenosynovitis, arthritis, bursitis,
and/or osteomyelitis and Type IV refers to disseminated
infection, lung involvement, and other systemic manifesta-
tions. Bacteremia is usually seen in immunocompromised
patients but is considered very rare [19, 20]. Our case was the
clinical manifestation of Type III infection.
In the literature, there are eleven cases whereM.marinum
presented with deep tissue infection and osteomyelitis. The
first case was published in 1972 involving a 36-year-old
healthy Vietnamese female who was exposed to salt water
and fishing presented with deep infection and osteomyelitis
of the hand leading to amputation. Among the eleven cases,
there were seven cases of immunocompetent patients and
four cases with underlined immunocompromised status as
listed in Table 1.Themajority of infections involved the upper
extremities. Ten out of eleven cases were treated with both
chemotherapy and extensive debridement, and four of them
required amputation. None of the eleven cases had Type IV
or disseminated infection nor bacteremia.
Diagnosis of M. marinum infection is usually delayed,
suggesting that most physicians are not familiar with the
disease [8]. This is probably because of the rareness of the
infection and a failure to establish a history of exposure
to aquatic environments or to tropical fish. Key diagnostic
elements for M. marinum infections are a high index of
suspicion raised by negative bacterial tissue cultures, poor
response to conventional antibiotic treatments, and a history
of aquatic exposure [6, 18]. A definite diagnosis is confirmed
by isolation and identification of the organism. All of the
cases reported listed in Table 1 had positive cultures for
M. marinum and the majority of the cases had history of
exposure to aquatic environments.
However, in practice, the diagnosis remains largely
presumptive, based on clinicohistological features and the
response to appropriate antimicrobial treatment, regardless
of culture results [6]. In addition, polymerase chain reaction
(PCR) allows the early detection of the organism from a
biopsy specimen. This technique may prove to be helpful
and supersede conventional methods in the rapid diagnosis
and species identification of nontuberculous infections and
become the test of choice in the future [9].
Occasional spontaneous resolution of soft tissue infection
by M. marinum has been reported in the literature. The
main purpose of therapy aims for a rapid recovery from
the infection and the prevention of progression to deeper
structures [5]. Monotherapy is usually applied for skin and
soft tissue infection, but this is considered ineffective for
deeper structure infections. Among eleven cases with deep
seated infection, only one was treated with Doxycycline
monotherapy for six months (Table 2).
There have been no comparative trials of different treat-
ment regimens for soft tissue infection by M. marinum. A
literature review that was published in 2007 suggests that top-
ical therapy as a sole treatment is completely ineffective and
unnecessary [6]. In limited superficial cutaneous infections
(Type I), the second-generation tetracycline minocycline
(100mg b.i.d.), clarithromycin (500mg b.i.d.), doxycycline
(100mg b.i.d.), and trimethoprim/sulfamethoxazole (800mg
b.i.d.), each as monotherapy, are considered effective treat-
ment options.
Based on the available literature review, a reasonable
approach is to treat patient with two active antimicrobials for
at least one to two months after resolution of symptoms [5–
7]. This is more so in immunocompromised individuals and
cases of severe cutaneous infections (Type II or III). Typical
duration of therapy is 3-4 months. Duration of treatment is
usually longer in patientswith deeper structure infections [6].
Because of the extensive involvement and slow recovery, our
patient treatment has been extended for nine months. In our
literature review, the longest duration of therapy documented
was for 18 months (Table 2).
M. marinum is usually susceptible to rifampin, rifabutin,
ethambutol, clarithromycin, sulfonamides or trimethoprim/
sulfamethoxazole, doxycycline, and minocycline [4, 5, 7].
In the literature, the most commonly used combinations
include clarithromycin and rifampin, clarithromycin and
ethambutol, or the combination of ethambutol and rifampin.
In our patient, M. marinum was resistant to rifampin and
unfortunately could not be used as one of the agents in
the combination regimen (Table 1). However, our patient
showed good response with the therapy of azithromycin and
trimethoprim/sulfamethoxazole combination.
In cases with severe cutaneous infections (Types I–III),
surgical treatment may be required if the infection has not
been controlled by chemotherapy. Deeper infections (Type
III) may require prolonged systemic treatment and repeated
surgical debridement. However, the selection of cases and
the time of surgical intervention require good judgment. In
disseminated infection or bacteremia (Type IV), combined
(antimicrobial plus antimycobacterial) intravenous therapy
of three drugs may be required [6, 9, 10].
The use of isoniazid, streptomycin, and pyrazinamide
as empirical treatment options should be avoided, as the
resistance of the organism to these agents is well documented
[6, 21]. Cryotherapy, X-ray therapy, electrodesiccation, pho-
todynamic therapy, and local hyperthermic therapy have also
been proposed as therapeutic alternatives, but there is so far
no solid evidence on the successful cure rate on these [21].
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In conclusion, infections due toM. marinum are uncom-
mon, but not rare. M. marinum infection should always be
included in the differential diagnosis of all cases with poorly
healing wounds in upper extremities and in persons with
a history of exposure to aquariums. The diagnosis requires
both a detailed history and sophisticatedmicrobiological and
PCR-based investigations. No large systemic studies have
been performed to determine the optimal treatment regimen.
In most cases a combination of antibacterial drugs should be
given as well as long-term therapy depending on the duration
and severity of infection.
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